Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1260298

BPC157 as Potential Agent Rescuing from Cancer Cachexia


Kang, Eun A.; Han, Young-Min; An, Jeong Min; Park, Yong Jin; Sikiric, Predrag; Kim, Deok Hwan; Kwon, Kwang An; Kim, Yoon Jae; Yang, Donghwa; Tchah, Hann; Hahm, Ki Baik
BPC157 as Potential Agent Rescuing from Cancer Cachexia // Current Pharmaceutical Design, 24 (2018), 18; 1947-1956 doi:10.2174/1381612824666180614082950 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 1260298 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
BPC157 as Potential Agent Rescuing from Cancer Cachexia

Autori
Kang, Eun A. ; Han, Young-Min ; An, Jeong Min ; Park, Yong Jin ; Sikiric, Predrag ; Kim, Deok Hwan ; Kwon, Kwang An ; Kim, Yoon Jae ; Yang, Donghwa ; Tchah, Hann ; Hahm, Ki Baik

Izvornik
Current Pharmaceutical Design (1381-6128) 24 (2018), 18; 1947-1956

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
BPC157 ; Cancer cachexia ; cytoprotection ; hypercatabolism ; hypoanabolism ; muscle atrophy

Sažetak
Cancer cachexia, one of the metabolic syndromes caused by cancer, is a devastating and miserable condition encountered in more than 50% of terminal cancer patients presenting with significant weight loss associated with skeletal muscle atrophy and fat loss. Though cachexia may account for up to 20% of cancer deaths, no significant treatment is still lacking and is of urgent unmet medical need in cancer treatment. Therefore, understanding the underlying molecular mechanisms is essential for anticipating therapeutic approaches. Since the primary events driving cachexia are mediated via either the central nervous system relatedor inflammation related-anorexia, hypoanabolism, and hypercatabolism, therapy usually targets nutritional support to compensate reduced food intake along with some anti-inflammatory agents to cover specific inflammation-related metabolic derangement, and encourages exercise to supplement reduced physical activity, but all proven to be not so effective so far. Therefore, combination therapies such as a standard multi-modal package including an anorexic agent, megestrol acetate, and anti-inflammatory agent coupled with the development of potential novel therapeutics promise a new era in rescuing patients from cancer cachexia. In this review, we propose the potential application of BPC157, one of the active cytoprotective agents isolated from gastric juices for cancer cachexia. Before clinical trial, we introduced the evidence showing BPC157 rescued from cancer cachexia supported with explored mode of actions.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti



POVEZANOST RADA


Projekti:
MZOS-108-1083570-3635 - Pentadekapeptid BPC 157 - daljnja istraživanja (Sikirić, Predrag, MZOS ) ( CroRIS)

Ustanove:
Medicinski fakultet, Zagreb

Profili:

Avatar Url Predrag Sikirić (autor)

Poveznice na cjeloviti tekst rada:

doi

Citiraj ovu publikaciju:

Kang, Eun A.; Han, Young-Min; An, Jeong Min; Park, Yong Jin; Sikiric, Predrag; Kim, Deok Hwan; Kwon, Kwang An; Kim, Yoon Jae; Yang, Donghwa; Tchah, Hann; Hahm, Ki Baik
BPC157 as Potential Agent Rescuing from Cancer Cachexia // Current Pharmaceutical Design, 24 (2018), 18; 1947-1956 doi:10.2174/1381612824666180614082950 (međunarodna recenzija, članak, znanstveni)
Kang, E., Han, Y., An, J., Park, Y., Sikiric, P., Kim, D., Kwon, K., Kim, Y., Yang, D., Tchah, H. & Hahm, K. (2018) BPC157 as Potential Agent Rescuing from Cancer Cachexia. Current Pharmaceutical Design, 24 (18), 1947-1956 doi:10.2174/1381612824666180614082950.
@article{article, author = {Kang, Eun A. and Han, Young-Min and An, Jeong Min and Park, Yong Jin and Sikiric, Predrag and Kim, Deok Hwan and Kwon, Kwang An and Kim, Yoon Jae and Yang, Donghwa and Tchah, Hann and Hahm, Ki Baik}, year = {2018}, pages = {1947-1956}, DOI = {10.2174/1381612824666180614082950}, keywords = {BPC157, Cancer cachexia, cytoprotection, hypercatabolism, hypoanabolism, muscle atrophy}, journal = {Current Pharmaceutical Design}, doi = {10.2174/1381612824666180614082950}, volume = {24}, number = {18}, issn = {1381-6128}, title = {BPC157 as Potential Agent Rescuing from Cancer Cachexia}, keyword = {BPC157, Cancer cachexia, cytoprotection, hypercatabolism, hypoanabolism, muscle atrophy} }
@article{article, author = {Kang, Eun A. and Han, Young-Min and An, Jeong Min and Park, Yong Jin and Sikiric, Predrag and Kim, Deok Hwan and Kwon, Kwang An and Kim, Yoon Jae and Yang, Donghwa and Tchah, Hann and Hahm, Ki Baik}, year = {2018}, pages = {1947-1956}, DOI = {10.2174/1381612824666180614082950}, keywords = {BPC157, Cancer cachexia, cytoprotection, hypercatabolism, hypoanabolism, muscle atrophy}, journal = {Current Pharmaceutical Design}, doi = {10.2174/1381612824666180614082950}, volume = {24}, number = {18}, issn = {1381-6128}, title = {BPC157 as Potential Agent Rescuing from Cancer Cachexia}, keyword = {BPC157, Cancer cachexia, cytoprotection, hypercatabolism, hypoanabolism, muscle atrophy} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font